Concord Drugs Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

9.32

8.74

8.74

8.74

7.86

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

22.39

19.62

18.02

14.74

15.29

Loan funds

Secured loans

14.80

16.43

12.97

9.57

9.83

Unsecured loans

-

-

-

-

-

Total

46.51

44.79

39.74

33.05

32.98

Uses of funds

Fixed assets

Gross block

37.61

37.12

35.22

10.52

11.85

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

24.75

23.15

21.39

-

-

Net block

12.86

13.97

13.83

10.52

11.85

Capital work-in-progress

0.92

0.55

-

1.00

0.29

Investments

1.42

-

-

-

-

Net current assets

Current assets, loans & advances

41.44

41.92

36.05

46.49

70.63

Less : current liabilities & provisions

10.13

11.65

10.14

24.96

49.79

Total net current assets

31.31

30.27

25.91

21.53

20.84

Miscellaneous expenses not written

-

-

-

-

-

Total

46.51

44.79

39.74

33.05

32.98

Notes:

Book value of unquoted investments

-

-

-

-

-

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

-

-

-

-

-

Number of equity sharesoutstanding (Lacs)

93.15

87.44

87.44

87.44

78.62